Benzinga | Jan 29, 2021 07:40AM EST

RBC Capital Initiates Coverage On IGM Biosciences with Outperform Rating, Announces Price Target of $121

RBC Capital analyst Brian Abrahams initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Outperform rating and announces Price Target of $121.